Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2025
Principal Office: Minneapolis, Minnesota
Trading Symbol: DMAC (Nasdaq)
This filing reports on a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the company's DM199 program for the treatment of preeclampsia.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory and clinical development updates.
Material Changes and Clinical Updates
- FDA Pre-IND Meeting: DiaMedica completed an in-person pre-IND meeting with the FDA for a planned study evaluating DM199 in pre-eclampsia.
- Regulatory Requirement: The FDA requested one additional non-clinical study: a 10-day modified embryo-fetal development (EFD) and pre- and postnatal development (PPND) study in a rabbit model.
- Study Status: Preparations for the required rabbit study have commenced.
- Timeline: Results from the rabbit study are expected to be available by the second quarter of 2026.
Outlook, Risks, and Management Commentary
Forward-Looking Statements: Management anticipates the rabbit study results in Q2 2026 and expects to proceed with a Phase 2 investigator-sponsored trial for preeclampsia. The company also maintains plans to develop DM199 for acute ischemic stroke.
Key Risks and Uncertainties:
- Timing and outcomes of non-clinical studies and clinical trials.
- Potential for existing preclinical data not to predict future clinical trial results.
- Ability to secure necessary funding for operations and trials.
- External factors including hospital staffing shortages, tariffs, and global supply chain disruptions.
- Reliance on third-party collaborators for clinical trial execution.
Investor Verification Checklist
- Verify the commencement and progress of the FDA-requested rabbit EFD/PPND study.
- Monitor the Q2 2026 timeline for the release of non-clinical study results.
- Assess the company's current cash runway and funding status to support the additional study and future Phase 2 trials.
- Review the full text of the press release (Exhibit 99.1) for detailed clinical rationale.